Organ-on-a-chip player Emulate has added $17 million to its Series B round and landed a deal with Covance.
A council chaired by President Obama has called for countries to cooperate to investigate the potential uses of artificial intelligence in healthcare.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Elemental Machines is shipping its sensor-enabled smart lab system to cut the time it takes to pinpoint causes of variability and reproducibility problems.
Amadeus Capital and Jonathan Milner have teamed up to invest in Healx, a startup working with patient advocacy groups to repurpose drugs for rare diseases.
Recursion Pharmaceuticals has raised $12.9 million to scale up its computer-driven approach to drug development.
UC San Francisco has landed $24 million in National Science Foundation funding to set up the Center for Cellular Construction.
British startup BenevolentAI has become the first European firm to install a purpose-built version of the DGX-1, a supercomputer designed for deep learning.
Antidote, the tech startup formerly known as TrialReach, is gearing up to introduce a tool to automatically match patients’ EHRs to clinical trials.
AOBiome is running an iPhone-enabled Phase IIb trial of its bacterial treatment for acne with Novartis ($NVS)-backed virtual trial CRO Science 37.
Researchers have found 110 antiviral targets and several existing drugs that may hit them using gene-trap insertional mutagenesis and a computational framework…